⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Form 8-K
sec.gov
NRIX
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
globenewswire.com
NRIX
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
globenewswire.com
NRIX
Nurix Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
NRIX
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
globenewswire.com
NRIX
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
globenewswire.com
NRIX